Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

Atkins, M. B., Jegede, O. A., Haas, N. B., Mcdermott, D. F., Bilen, M. A., Stein, M., Sosman, J., Alter, R., Plimack, E. R., Ornstein, M. C., Hurwitz, M., Peace, D. J., Einstein, D., Catalano, P. J., Hammers, H., & Regan, M. M. (2024). Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). Journal for ImmunoTherapy of Cancer, 12(4), e008293. https://doi.org/10.1136/jitc-2023-008293
Authors:
Michael B. Atkins
Opeyemi A. Jegede
Naomi B. Haas
David F. McDermott
Mehmet Asım Bilen
Mark N. Stein
Jeffrey A. Sosman
Robert S. Alter
Elizabeth R. Plimack
Moshe Chaim Ornstein
Michael E. Hurwitz
David Peace
David J. Einstein
Paul J. Catalano
Hans J. Hammers
Meredith M. Regan
Affiliated Authors:
Mark N. Stein
Columbia Affiliation:
Subjects:
Renal Cell Carcinoma (OpenAlex Topic)
Cancer Immunotherapy (OpenAlex Topic)
Genomic Landscape of Cancer and Mutational Signatures (OpenAlex Topic)
Author Keywords:
immunotherapy
immune checkpoint inhibitors
renal cell carcinoma
clinical trials as topic
elink
Publication Type:
Article
Unique ID:
10.1136/jitc-2023-008293
PMID:
38604810
DOI:
10.1136/jitc-2023-008293
Journal:
Journal for ImmunoTherapy of Cancer
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record
View Web of Science Record

Record Created: